Biotech's great run has been achieved despite a number of macroeconomic events along the way that periodically spooked the general markets, but left the confidence in the industry largely unscathed. Although the sector has managed to shrug off those stock market perturbations, it was a different story at the end of second quarter as the markets headed south.